Tango Therapeutics Files Q1 2025 10-Q
Ticker: TNGX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1819133
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Tango Tx Q1 2025 10-Q filed. Financials updated, focus on debt securities & fair value.
AI Summary
Tango Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations. Key financial items include details on marketable debt securities and security deposits, with specific references to US Treasury Securities and Fair Value Measurements Level 2.
Why It Matters
This filing provides investors with an update on Tango Therapeutics' financial health and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 20250512 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 0000950170-25-068549 (other) — Accession Number
- BCTG Acquisition Corp. (company) — Former company name
- 20200723 (date) — Date of name change
FAQ
What is the primary focus of the financial disclosures in this 10-Q filing?
The filing highlights details regarding marketable debt securities, security deposits, and fair value measurements, particularly concerning US Treasury Securities classified under Level 2 inputs.
When did Tango Therapeutics change its name from its former entity?
Tango Therapeutics, Inc. changed its name from BCTG Acquisition Corp. on July 23, 2020.
What is the Standard Industrial Classification (SIC) code for Tango Therapeutics?
The SIC code for Tango Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
What period does this 10-Q filing cover?
This 10-Q filing covers the fiscal quarter ending on March 31, 2025.
Where is Tango Therapeutics headquartered?
Tango Therapeutics, Inc. is headquartered in Boston, MA, with its business and mail address listed as 201 Brookline Avenue, Suite 901, Boston, MA 02215.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Tango Therapeutics, Inc. (TNGX).